SynthesisReviews in medical virology2023
Safety and immunogenicity of Zika virus vaccine: A systematic review of clinical trials.
Synthesis in Reviews in medical virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Safety and immunogenicity of Zika virus vaccine: A systematic review of clinical trials.Reviews in medical virology · 2023Pooled it
- Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial.Human vaccines & immunotherapeutics · 2025Trial
- Intranasal MyD88-adjuvanted DNA vaccine against P. gingivalis in rat periodontitis.BMC oral health · 2026Article
- An updated review of Zika virus vaccine development.Clinical and experimental vaccine research · 2025Review
- Virus-like particle vaccine with authentic quaternary epitopes protects against Zika virus-induced viremia and testicular damage.Journal of virology · 2025Article
- Congenital Zika virus infection in laboratory animals: a comparative review highlights translational studies on the maternal-foetal interface.Memorias do Instituto Oswaldo Cruz · 2025Review
- Evidence map of strategies for preventing and controllingRevista panamericana de salud publica = Pan American journal of public health · 2025Review
- The inoculum dose of Zika virus can affect the viral replication dynamics, cytokine responses and survival rate in immunocompromised AG129 mice.Molecular biomedicine · 2024Article
- Article
- Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets.NPJ vaccines · 2024Article
- Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice.NPJ vaccines · 2024Article
- A review on Zika vaccine development.Pathogens and disease · 2024Review
- Insight into the Natural Biomolecules (BMs): Promising Candidates as Zika Virus Inhibitors.Infectious disorders drug targets · 2024Review
- Arthropod-Borne Flaviviruses in Pregnancy.Microorganisms · 2023Review
- Development of a risk model to predict prognosis in breast cancer based on cGAS-STING-related genes.Frontiers in genetics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several phase-1 clinical trials have been performed to evaluate the safety and efficacy of candidate anti-Zika vaccines. In this systematic review, we systematically evaluated the safety and immunogenicity of candidate vaccines, which would aid researchers in formulating an effective vaccination strategy for phase-2 trials based on current evidence. A literature search was conducted using the electronic databases MEDLINE through Pubmed, Web of Science, and Cochrane Database for relevant studies on candidate anti-zika vaccines. Studies on animal models were excluded from our study. Healthy individuals who were administered candidate Zika vaccines to evaluate the immune response and adverse events (AEs) compared to placebo were considered. Data were extracted, tabulated, and analysed using Microsoft Excel, while the risk of bias plots were generated using tidyverse and Robvis packages in R-studio. A total of five phase-1 clinical trials were included in our analysis comprising of studies on inactivated, viral vector, and DNA vaccines. Immunogenicity ranged from 10% to 100% after vaccination with the lowest seroconversion rate (10%) and geometric mean titre (GMT) (6.3; 95% confidence interval (CI):3.7-10.8) observed among recipients of single-dose inactivated anti-zika vaccine (ZPIV). For DNA vaccines, the seroconversion rate ranged from 60% to 100% with the highest seroconversion rate (100%) and GMT (2871; 95% CI:705.3-11688) observed among recipients of three shots of high dose GLS-5700 vaccine. For viral vector vaccine (Ad26.ZIKV.001) seroconversion rate (100%) and GMT peaked after two shots with both low and high-dose vaccines. In all those studies AEs were mostly local including injection site pain, erythema, and itching. The most common systemic AEs included fever, myalgia, nausea, and fatigue. In phase-1 clinical trials, all candidate vaccines were found to be highly immunogenic and relatively safe, especially when administered in higher doses and with the help of needle-free devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.